Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00586196
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 915
- Registration Number
- NCT00566501
- Locations
- 🇺🇸
Apex Research Institute, Santa Ana, California, United States
Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone
- Conditions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Ludwig Boltzmann Gesellschaft
- Target Recruit Count
- 80
- Registration Number
- NCT00533065
- Locations
- 🇦🇹
Ludwig Boltzmann Institute, Vienna, Austria
Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment
- Conditions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT00530478
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00519298
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2008-12-29
- Lead Sponsor
- Hospital Miguel Servet
- Target Recruit Count
- 64
- Registration Number
- NCT00505167
- Locations
- 🇪🇸
Hospital de Barbastro, Barbastro, Huesca, Spain
🇪🇸Hospital Royo Villanova, Zaragoza, Spain
🇪🇸Cenro de especialidades San José. Hospital Miguel Servet, Zaragoza, Spain
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 659
- Registration Number
- NCT00501111
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 22
- Registration Number
- NCT00482001
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦Lakehead University, Thunder Bay, Ontario, Canada
The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2007-12-04
- Lead Sponsor
- Associacao Fundo de Incentivo a Psicofarmcologia
- Target Recruit Count
- 65
- Registration Number
- NCT00480870
- Locations
- 🇧🇷
Instituto do Sono, Sao Paulo, Brazil
Neural Correlates In Mild Alzheimer's Disease
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00477659
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.